Nutritional and Metabolic Diseases

441 trials 157 recruiting

Filter these 441 trials by phase, country and sponsor.

Open in Search →

Fast-Acting Insulins and Their Post-Meal Effects in Type 1 Diabetes Ended

2023-509217-37-00 Type 1 Diabetes 3 2024-06-25
LIBERAL Study Ended

2023-507823-52-00 Patients with chronic kidney disease stage 3b to 4 5 2024-05-27
A study to test how BI 456906 is taken up in the blood of people with and without kidney problems Ended

2023-508557-13-00 Renal impairment (mild, moderate and severe) 3 2024-05-08
A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without T… Ended

2023-504583-42-00 Overweight or Obesity and Chronic Kidney Disease With o 4 2024-05-07
Investigating how CagriSema, semaglutide and cagrilintide regulate insulin effects in the body of people with type 2 diabetes. Ended

2023-509483-20-00 Type 2 diabetes 3 2024-04-26
The Attractive 2 trial – An open-label, randomised, 2-period cross-over trial to assess the pharmacokinetics of ATR-258 oral capsule vs. ora… Ended

2023-508797-28-00 Type 2 diabetes (T2D) 3 2024-04-24
A research study to see if kidney damage in people with chronic kidney disease and type 2 diabetes living with overweight or obesity can be … Ended

2023-505857-42-00 Chronic Kidney Disease, Type 2 diabetes 4 2024-04-19
A study in people with overweight or obesity to test how BI 1820237, BI 456906, or a combination of both affects brain activity Ended

2023-506233-30-01 Obesity 3 2024-04-15
REIMAGINE 3: A research study to see how much CagriSema lowers blood sugar and body weight compared to placebo in people with type 2 diabete… Ended

2022-502679-43-00 Type 2 diabetes 5 2024-04-12
A Research Study to See How Switching from a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar … Ended

2023-506084-34-00 Type 2 Diabetes 5 2024-04-12
A study to assess the efficacy and safety of tigulixostat at different doses as compared to a control drug (allopurinol) in gout patients wi… Ended

2022-501421-20-00 Gout with hyperuricemia 5 2024-04-09
A research study Looking into blood levels of the medicine NNC0519-0130 in the body of participants with normal or reduced kidney function Ended

2023-506381-32-00 Type 2 Diabetes Mellitus 1 2024-03-25
GLP-1 receptor agonists as preventive treatment of diabetes after renal transplantation: a single-arm interventional clinical trial. Study 2… Ended

2023-506436-33-00 Metabolic syndrome in patients on the waiting list for 5 2024-03-22
A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control W… Ended

2023-507206-13-00 Type 2 Diabetes 5 2024-03-14
A PHASE I, OPEN-LABEL, RANDOMIZED, ADAPTIVE, CROSS-OVER STUDY TO DETERMINE THE RELATIVE BIOAVAILABILITY OF NIZUBAGLUSTAT CAPSULES COMPARED T… Ended

2023-510058-17-00 Glycosphingolipid lysosomal storage disorders 3 2024-03-12
Functional Constipation: Linaclotide versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, with Functional Constipation (FC) Ended

2022-501946-31-00 Functional Constipation 5 2024-02-29
A24110He in a placebo-controlled trial evaluating safety in subjects with elevated plasma triglycerides Ended

2023-509091-42-00 Moderate to severe hypertriglyceridemia 4 2024-02-27
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or With… Ended

2023-507280-18-00 Type 2 Diabetes 5 2024-02-23
A study to test how a new long-acting insulin works in the body of patients with type 2 diabetes during exercise and prolonged fasting. Ended

2023-505012-38-00 Type 2 diabetes 3 2024-02-21
A research study to look at how CagriSema influences food intake, appetite and emptying of the stomach in people with excess body weight Ended

2023-504792-24-00 Obesity 3 2024-02-20
A study of how CagriSema works on appetite in people with excess body weight Ended

2023-504782-23-00 Obesity 3 2024-02-09
A research study to see how well new weekly medicine IcoSema, which is a combination of insulin icodec and semaglutide, controls blood sugar… Ended

2022-502484-38-00 Type 2 diabetes 5 2024-02-07
A research study of a new medicine (NNC0650-0013) in healthy men Ended

2023-506134-79-00 Weight management, Diabetes mellitus type 2; healthy su 1 2024-01-23
Finerenone and renal oxidative stress Ended

2023-508266-15-00 type 2 diabetes mellitus 5 2024-01-18